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Impact of Tumour Epithelial Subtype on Circulating
microRNAs in Breast Cancer Patients
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Maria Duignan1, Mark McLoughlin1, John Newell2, Michael J. Kerin1
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and Applied Mathematics, National University of Galway, Galway, Ireland

Abstract
While a range of miRNAs have been shown to be dysregulated in the circulation of patients with breast cancer, little is
known about the relationship between circulating levels and tumour characteristics. The aim of this study was to analyse
alterations in circulating miRNA expression during tumour progression in a murine model of breast cancer, and to detemine
the clinical relevance of identified miRNAs at both tissue and circulating level in patient samples. Athymic nude mice
received a subcutaneous or mammary fat pad injection of MDA-MB-231 cells. Blood sampling was performed at weeks 1, 3
and 6 following tumour induction, and microRNA extracted. MicroRNA microArray analysis was performed comparing
samples harvested at week 1 to those collected at week 6 from the same animals. Significantly altered miRNAs were
validated across all murine samples by RQ-PCR (n = 45). Three miRNAs of interest were then quantified in the
circulation(n = 166) and tissue (n = 100) of breast cancer patients and healthy control individuals. MicroArray-based analysis
of murine blood samples revealed levels of 77 circulating microRNAs to be changed during disease progression, with 44
demonstrating changes .2-fold. Validation across all samples revealed miR-138 to be significantly elevated in the
circulation of animals during disease development, with miR-191 and miR-106a levels significantly decreased. Analysis of
patient tissue and blood samples revealed miR-138 to be significantly up-regulated in the circulation of patients with breast
cancer, with no change observed in the tissue setting. While not significantly changed overall in breast cancer patients
compared to controls, circulating miR-106a and miR-191 were significantly decreased in patients with basal breast cancer. In
tissue, both miRNAs were significantly elevated in breast cancer compared to normal breast tissue. The data demonstrates
an impact of tumour epithelial subtype on circulating levels of miRNAs, and highlights divergent miRNA profiles between
tissue and blood samples from breast cancer patients.
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miRNAs to be differentially expressed between molecular tumour
subtypes [6,7,8]. However the relationship between circulating
and tissue miRNAs, and the impact, if any, of tumour subtype on
circulating miRNAs requires further elucidation.
Despite significant progress in breast cancer research, a reliable
biomarker with appropriate sensitivity and specificity for detection
of early disease has yet to be identified. Mammography remains
the gold standard for breast cancer screening. To date it has been
reported that screening mammography has a sensitivity ranging
from 62.9%–87% [9,10,11]. The use of CA15.3 as an adjunct in
screening and prognostication is also limited since it is only raised
in 10% of stage I and 20% stage II breast cancers [12,13].
Therefore the need for a specific, sensitive and non-invasive
biomarker for the detection of disease, or to indicate recurrence or
response to therapy is critical [14].
This group recently published a study investigating the use of a
murine model of breast cancer for analysis of circulating miRNAs
previously implicated in breast cancer [15]. The aim of this study
was to use microArrays to analyse alterations in circulating

Introduction
Interest in microRNAs as potential non-invasive biomarkers of
disease continues to grow as a result of their presence in the
circulation. These short, non-coding nucleotide sequences play a
pivotal role in gene regulation within the cell through translational
repression of target mRNAs [1]. Evidence of their dysregulation in
the circulation of patients with various cancer types has stimulated
intensive investigation into their potential for detection of disease
development or recurrence, determination of patient prognosis,
and indication or prediction of reponse to therapy [2,3]. It remains
unclear whether circulating miRNAs originate from the diseased
tissue itself, or as a result of host response to disease.
Breast cancer is a heterogeneous disease, and although mortality
rates are decreasing, incidence continues to rise [4]. Stage of
disease at diagnosis is directly related to outcome so early detection
is key. Breast cancer is known to comprise of several distinct
molecular subtypes, with subtype of disease also having a major
impact on outcome [5]. A number of studies have also found
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Table 1. Clinicopathological characteristics of patients from whom blood samples were harvested for analysis of circulating
microRNAs.

Breast Cancer (n = 83)

Controls (n = 83)

57.2

57.1

Pre

33

37

Post

49

45

Peri

1

1

Mean Patient Age (yr)
Menopausal Status

Histological Subtype
Luminal A

31

Luminal B

11

Her2/neu

18

Basal

23

Tumour Grade
1

9

2

38

3

36

Tumour Stage
1

25

2

46

3

12

doi:10.1371/journal.pone.0090605.t001

miRNA expression during tumour progression to potentially
identify novel miRNAs associated with disease. Following validation in murine samples, identified targets were then applied to
blood and tissue samples from breast cancer patients and healthy
control individuals to determine their true relevance in the clinical
setting. Any relationship between the circulating miRNAs of
interest and tumour epithelial subype was also investigated.

Table 2. Top ten microRNAs demonstrating greatest changes
in circulating levels in animals from week 1 to week 6 during
tumour progression.

Target
miR-138

Materials and Methods

miR-128a

Cell Culture

miR-323-3p

The breast cancer cell line MDA-MB-231 was obtained from
the American Type Culture Collection (ATCC), and cultured in
Leibowitz-15 (L-15), supplemented with 10% fetal bovine serum
(FBS), and 100 IU/ml and Penicillin G (2 units/mL)/Streptomycin sulphate (100 mg/mL).

miR-574-3p
miR-106a
miR-191
miR-202
miR-744

In Vivo Model

miR-486

All animal experiments were licensed, and ethical approval was
received from the National University of Ireland Galway Animal
Care Research Ethics Committee. Similar to previous experiments
[15], fifteen female athymic nude mice (Harlan Sprague-Dawley,
Indianapolis, IN) received a mammary fat pad (MFP, n = 8) or
subcutaneous right flank (SC, n = 7) injection of 26105 or 46105
respectively of MDA-MB-231 cells in 0.2 ml 50% Matrigel
medium. Blood sampling was carried out on all animals from
the lateral tail vein at weeks 1, 3 and 6 following induction (total
n = 45). Blood was stored at 4uC in 2 ml EDTA tubes until
required. At week 6 all mice were sacrificed by CO2 inhalation.

miR-130a
doi:10.1371/journal.pone.0090605.t002

the principles of the Declaration of Helsinki. All blood samples
(total n = 166: n = 83 pre-operative breast cancer, n = 83 healthy
controls, Table 1) were stored in 10 ml Vacuette EDTA tubes
(Grenier Bio-one) at 4uC. Breast tissue specimens (total n = 100:
n = 60 breast cancer, n = 40 reduction mammaplasty controls)
were obtained from patients undergoing surgery at Galway
University Hospital, Galway, Ireland. Following excision, tissue
samples were preserved in RNAlaterH and then stored at 280uC
until RNA extraction. Clinicopathological details were retrieved
on each patient and are shown in Table 1.

Patient Samples
Written informed consent was obtained from each patient prior
to sample collection, and the study was approved by the ethics
review board of Galway University Hospital, and cpmplied with
PLOS ONE | www.plosone.org
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Table 3. Selection of 44 microRNAs found to be commonly dysregulated in the circulation of 4/5 animals as tumours progressed.

hsa-let-7b-002619

hsa-miR-126-002228

hsa-let-7d-002283

hsa-miR-130a-000454

hsa-let-7e-002406

hsa-miR-130b-000456

hsa-let-7g-002282

hsa-miR-140-3p-002234

hsa-miR-15b-000390

hsa-miR-142-3p-000464

hsa-miR-16-000391

hsa-miR-146b-001097

hsa-miR-17-002308

hsa-miR-186-002285

hsa-miR-19a-000395

hsa-miR-191-002299

hsa-miR-19b-000396

hsa-miR-195-000494

hsa-miR-20a-000580

hsa-miR-92a-000432

hsa-miR-21-000397

hsa-miR-92a-000432

hsa-miR-24-000402

hsa-miR-92a-000432

hsa-miR-25-000403

hsa-miR-106a-002170

hsa-miR-26a-000405

hsa-miR-106b-000443

hsa-miR-26b-000407

hsa-miR-126-002229

hsa-miR-29a-002112

hsa-miR-130a-000455

hsa-miR-30b-000602

hsa-miR-130b-000457

hsa-miR-30c-000419

hsa-miR-140-3p-002235

hsa-miR-31-002279

hsa-miR-142-3p-000465

hsa-miR-92a-000431

hsa-miR-146b-001098

hsa-miR-106a-002169

hsa-miR-186-002286

hsa-miR-106b-000442

hsa-miR-191-002300

doi:10.1371/journal.pone.0090605.t003

Array-based analysis of blood samples resulted in detection of a
selection of microRNAs, and the entire data set is deposited in the
Gene Expression Omnibus(GEO) archive : GEO accession no.
GSE47455.

microRNA Extraction
microRNA was extracted from 50 uL of murine blood or 1 mL
of human blood using a modification of the TRI Reagent BD
technique (Molecular Research Centre, Inc.) as described previously [16]. Total RNA was extracted from patient tissue using the
RNeasy kit (Qiagen) according to manufacturers instructions.
Sample concentration and purity were assessed by NanoDropTM
1000 spectrophotometry (Nanodrop Technologies, Wilmington,
DE, USA) and also using the RNA 6000 Nano Lab Chip Series II
Assay with the 2100 Bioanalyzer System (Agilent Technologies,
Palo Alto, CA, USA).

Analysis of microRNA Expression
Real-Time Quantitative Polymerase Chain Reaction (RQPCR) quantification of miRNA expression was performed using
TaqManH MicroRNA Assays (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s protocol. MiRNA
(100 ng) was reverse-transcribed using the MultiScribeTM-based
High-Capacity cDNA Archive kit (Applied Biosystems). RTnegative controls were included in each batch of reactions. PCR
reactions were carried out in final volumes of 10 ml using on a
7900 HT Fast Real-Time PCR System (Applied Biosystems).
Briefly, reactions consisted of 0.7 ml cDNA, 16TaqManH
Universal PCR Master Mix, 0.2 mM TaqManH primer–probe
mix (Applied Biosystems). Reactions were initiated with 10-minute
incubation at 95uC followed by 40 cycles of 95uC for 15 seconds
and 60uC for 60 seconds. Expression of miR-138, miR-106a and
miR-191 was examined in patient samples. U6 and let-7a were
used as endogenous controls to standardize miRNA expression for
blood and tissue respectively [17]. Triplicate samples, validated
endogenous controls, and interassay controls were used throughout. MiRNA expression levels were calculated and the threshold
standard deviation for intra-assay and inter-assay replicates was ,
0.3. The relative quantity of miRNA expression was calculated
using the comparative cycle threshold (DDCt) method [18], and
the lowest expressed sample was used as a calibrator.

MicroRNA microArray
TaqMan Low Density microRNA Array Card A v2 (Applied
Biosystems) were employed, consisting of 384-well microfluidics
cards targeting well-characterised miRNAs with U6 included as an
endogenous control. Five animals (three animals with MFP
tumours and two with SC tumours), with corresponding blood
samples at week 1 and week 6 were included in the study (10
murine samples in total). A total of ten microarrays were
performed, with whole blood sampled one week following tumour
induction and again at 6 weeks in the presence of progressive
disease. During internal validation the change in microRNA
profile was then analysed across all murine blood samples at week
1, week 3 and week 6, with the ‘‘early’’ sample providing the
baseline measurements for each animal (n = 45). Assays were run
on the 7900HT Fast Real-Time polymerase chain reaction (PCR)
machine(Applied Biosystems). MiRNAs were ranked according to
their degree of dysregulation in relative fold change. After
validation across all murine samples (n = 45), three miRNAs of
interest were translated into a breast cancer patient cohort and
circulating (n = 166) and tissue (n = 100) levels quantified. MicroPLOS ONE | www.plosone.org

3

March 2014 | Volume 9 | Issue 3 | e90605

Circulating microRNAs in Breast Cancer Patients

Figure 1. Validation of changes in circulating levels of microRNAs identified using microArray analysis in murine blood samples at
week1, week 3 and week 6 following tumour induction (A) Circulating miR-138 (B) Circulating miR-191 (C) Circulating miR-106a. *
denotes outliers.
doi:10.1371/journal.pone.0090605.g001

Results

Statistical Analysis
Due to the magnitude and range of relative miRNA expression
levels observed, results data were log transformed for analysis.
Data are presented as mean+/2SD. There was no evidence
against normality for the log transformed data as confirmed using
the Kolmogorov-Smirnov test. The 2-sample t test was used for all
2 sample comparisons and ANOVA, followed by Tukey HSD post
hoc test for inter-sample comparisons. All tests were 2-tailed and
results with a P,0.05 were considered statistically significant.
Analysis was performed in MinitabH Statistical Software (version
16.0; PA, USA) for windows.

MicroRNA microArray
When samples from individual animals taken one or six weeks
following tumour induction were compared, levels of 77 circulating microRNAs were found to be changed during disease
progression, with the ten miRNAs demonstrating greatest change
summarised in Table 2. Analysis was further performed to focus
on targets with changes .2-fold, that were common to 4 animals
(n = 44, Table 3).

Validation of microArray Data in Murine Samples
miR-138, miR-191 and miR-106a were then selected and
further validated across all murine blood samples (total n = 45:
n = 15 week 1, n = 15 week 3, n = 15 week 6). In agreement with
the microArray data, analysis of all murine samples (n = 45)
revealed miR-138 to be significantly elevated in the circulation of
animals during disease development (p,0.05, Figure 1A). Although found to be altered on microArray, no significant change
in circulating miR-191 during disease progression was observed
(p = 0.19, Figure 1B). However, when investigated in the blood of
mice bearing subcutaneous tumours, miR-191 was significantly
downregulated over time (p,0.05, results not shown). Further
analysis of miR-106a revealed a significant decrease from week 1

Ethical Standards
All animal experiments were licensed, and ethical approval was
received from the National University of Ireland Galway Animal
Care Research Ethics Committee. Written informed consent was
obtained from each patient prior to sample collection, and the
study was approved by the ethics review board of Galway
University Hospital, and cpmplied with the principles of the
Declaration of Helsinki.

PLOS ONE | www.plosone.org
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Figure 2. miR-138 levels in (A) Circulation and (B) tissue of Breast Cancer Patients and healthy controls. Levels in breast cancer patients
were further subdivided based on epithelial subtype of the disease. * denotes outliers.
doi:10.1371/journal.pone.0090605.g002

(Mean 6 SEM; 2.3960.08 log10 Relative Quantity (RQ)) to week
6 (1.6160.1 log10 RQ, Figure 1C).

were also investigated in tumour tissue(n = 60) and healthy tissue
harvested at reduction mammoplasty(n = 40). No significant
dysregulation was observed with miR-138 expression when
comparing tumour to normal tissue. Interestingly, however,
miR-138 was significantly dysregulated across breast cancer
subtypes (ANOVA p,0.01), with higher levels detected in the
HER2 and basal subtype tissues (Figure 2B).
miR-191 was not significantly altered overall in breast cancer
patients compared to controls (Figure 3A). However, circulating
levels of the microRNA were significantly dysregulated across
epithelial subtype (ANOVA p,0.05), with the lowest levels
observed in patients with Basal breast cancer (Figure 3A). In
contrast, tissue levels of miR-191 were significantly higher in

Translation Into Patient Samples - Circulating and Tissue
Levels of microRNAs
miR-138, miR-191, and miR-106a were detectable in the
circulation of all breast cancer patients and healthy controls
included in the study (n = 166). miR-138 was found to be
significantly up-regulated in the circulation of patients with breast
cancer (2.0560.06 log10 RQ) compared to healthy controls
(1.8360.05, log10RQ, p,0.005, Figure 2A). No relationship with
tumour epithelial subtype was observed. The levels of this miRNA

PLOS ONE | www.plosone.org
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Figure 3. miR-191 levels in (A) Circulation and (B) tissue of Breast Cancer Patients and healthy controls. Levels in breast cancer patients
were further subdivided based on epithelial subtype of the disease. * denotes outliers.
doi:10.1371/journal.pone.0090605.g003

breast cancer patients compared to healthy controls (p,0.001,
Figure 3B). Further, expression of miR-191 was significantly
altered across epithelial subtype(p,0.001), with higher levels
detected in the Her2 and Basal subtypes.
Similarily, circulating miR-106a was not significantly altered
overall in breast cancer patients compared to controls (Figure 4A).
However, as observed with miR-191, miR-106a displayed
differential expression across epithelial subtype (ANOVA p,
0.05). Indeed, when evaluated in isolation, both miR-191 and
miR-106a were significantly down-regulated in patients with basal
breast cancer compared to healthy controls (p,0.05, p,0.005
respectively). miR-106a was also found to be significantly elevated
PLOS ONE | www.plosone.org

in breast tumour compared to healthy breast tissue (p,0.001,
Figure 4B). No significant correlation to patient clinicopathological
characteristics such as tumour stage, grade or menopausal status
was observed.

Discussion
MicroRNAs have tremendous potential as circulating biomarkers of diesase, however challenges remain to their successful
application in the clinical setting. In a heterogeneous disease such
as breast cancer, the impact of tumour characteristics on
circulating miRNAs, and indeed the relationship between
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Figure 4. miR-106a levels in (A) Circulation and (B) tissue of Breast Cancer Patients and healthy controls. Levels in breast cancer
patients were further subdivided based on epithelial subtype of the disease. * denotes outliers.
doi:10.1371/journal.pone.0090605.g004

circulating and tissue levels, require further investigation. The
current study describes analysis of circulating miRNAs in an
animal model of breast cancer over 6 weeks of tumour progression.
A selection of dysregulated miRNAs were then validated within
the murine samples and targets of interest further investigated in
tissue and blood samples harvested from breast cancer patients
and healthy control individuals.
miR-138, analysis of which has not previously been reported in
patient samples, was identified as a potential circulating marker of
breast cancer, with levels significantly elevated over time as
tumours progressed in animals. This held true in the larger
validation cohort and further, levels were found to be significantly
PLOS ONE | www.plosone.org

elevated in the circulation of breast cancer patients compared to
healthy controls. This data hightlights the validity of the murine
model used to identify potentially important circulating miRNAs
that are translatable to the patient setting. Indeed it may be
interesting to compare circulating levels in mice bearing tumours
originating from varying molecular subtypes of breast cancer.
Although there are inherent flaws to any model system, a major
benefit is that other comorbidities or confounding factors in
patients that may impact circulating miRNAs are absent from the
animal model.
Although miR-138 has not previously been analysed in breast
tissue samples, on a cellular level it has been implicated as a
7
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tumour suppressor [19,20,21], potentially through targeting
Neutrophil gelatinase-associated lipocalcin(NGAL) [19] or
hTERT [21]. In the current study, on a tissue level, miR-138
expression was not significantly changed in breast tumour samples
compared to healthy controls, but was found to be significanlty
altered across epithelial subtype, with the highest levels detected in
Her2 amplified samples.
Both miR-191(in subcutaneous model) and miR-106a were
found to decrease at a circulating level in the murine model, but in
patient blood samples there was no significant difference between
levels in breast cancer patients and healthy controls. Considering
the murine model used was based on injection of the basal breast
cancer cell line MDA-MB-231, it was interesting to find that in
both cases circulating levels were signfiicantly decreased in patients
with basal breast cancer compared to healthy controls. It is
noteworthy that at a tissue level, miR-191 was previously reported
to have lower expression in ER negative tumours compared to ER
positive [22]. It has also been known to fuction as a tumour
supressor through regulation of CDK6 in thyroid cancer [23].
MiR-106a has also been associated with basal breast cancer in the
tissue context, although levels were reported to be elevated rather
than decreased supporting its role as an oncomiR [7,24]. Reported
target genes of miR-106a include RUNX3, resulting in multidrug
resistance in gastric cancer [25]. Hu et al [26] previously analysed
miR-191 levels in serum of breast cancer patients and healthy
controls, and similar to the current findings reported no significant
difference, and further suggested use of miR-191 as an endogenous
control. However in that study all samples were pooled and so not
stratified based on tumour characteristics [26].
The data presented here highlights divergent miRNA profiles
observed between tissue and blood samples from breast cancer
patients, and support the idea that selected miRNAs may play a
more important role in the tumour microenvironment than in the
circulation. Further understanding of the factors contributing to
circulating levels of miRNAs, and the impact of tumour, and other

patient characteristics, on the miRNA profile is key to their
successful implementation as biomarkers of disease.
A number of studies have previously reported elevation of miR191 in tissue of a variety of cancer types including lung [27],
hepatocellular [28] and breast [22,29]. Similarily, miR-106a has a
well chacterized asoociation with cancer, and has been reported to
be upregulated in breast cancer compared to control tissue [30].
While not elevated at a circulating level, the current study also
found signficantly elevated levels of miR-191 and miR-106a in
breast cancer compared to normal breast tissue harvested at
reduction mammaplasty.

Conclusions
Fluctuations in miRNA levels during tumour development, and
determination of whether particular miRNAs could be indicative
of tumour subtype or aid selection of optimal treatment strategies
will be key to successful implementation in the clinical setting.
MiRNAs that are detectable at the early stages of tumourigenesis
have the potential to be used as a screening tool alongside CA 15.3
and mammography to improve early breast cancer detection.
Identification of the optimal panel of miRNAs for disease
diagnosis, prediction of prognosis, or response to therapy will be
dependent upon progress in this area.
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